ASH 2021

Conference Coverage

No EFS Benefit With Second-Line Tisa-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

The median event-free survival was 3 months in both treatment arms.

First-Line Ivosidenib Plus Azacitidine Prolonged Survival in IDH1-Mutated AML

The combination of ivosidenib plus azacitidine significantly prolonged OS with a median of 24.0 months compared with 7.9 months with placebo plus azacitidine.

Duration of TKI Treatment Predicts Early, Late Recurrence in Chronic Myeloid Leukemia

The underlying mechanisms of late recurrence must be investigated further, according to researchers.

Pola-R-CHP Outperforms Standard Care for Diffuse Large B-Cell Lymphoma

Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.

Allo-HSCT Improves Survival in Patients With TP53-Mutated Acute Myeloid Leukemia

Researchers analyzed treatment trends and outcomes over time to identify the optimal management strategy for TP53-mutated AML.

Naratuximab Emtansine Plus Rituximab: A New Treatment Option for Rel/Ref Non-Hodgkin Lymphoma?

The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.

Guadecitabine Is Not Superior to Standard Care in Patients With Pretreated Acute Myeloid Leukemia

Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.

Treatment With Azacitidine, Lenalidomide and Donor Lymphocyte Infusion in Myeloid Malignancies After Relapse Following Allo-SCT

Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.

Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

Low-Dose Inotuzumab Ozogamicin May Be Safe and Effective in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.

Racial/Ethnic and Socioeconomic Disparities in Outcomes Among Children With Acute Lymphoblastic Leukemia

Researchers sought to determine whether there are disparities by race/ethnicity and socioeconomic status in survival outcomes of children with ALL.

Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML

Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.

CAR-T Therapy May Improve Outcomes in Second-Line Relapsed/Refractory LBCL

Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.

Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma

A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.

Mesenchymal Stromal Cells Plus Second-Line Therapy Appears Efficacious in Steroid-Resistant Acute Graft-vs-Host Disease

The study included 203 patients with steroid-resistant acute GVHD who were treated at 10 centers in China between September 2014 and March 2019.

Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes

Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.

COVID-19 Mortality Higher in Blood Cancer Patients Than in General Population

Factors associated with an increased risk of death were older age, male sex, a pre-COVID-19 prognosis of 6 months or less, and deferring ICU care.

Circulating Tumor DNA Could Be Used to Diagnose, Guide Treatment of CNS Lymphoma

Circulating tumor DNA status before and during treatment predicted progression-free and overall survival.

CAR T-Cell Therapy Bests Standard Care for Relapsed/Refractory Large B-Cell Lymphoma

Axicabtagene ciloleucel improved responses and prolonged event-free survival.

Long-Term Data Confirm Benefits of Treatment De-Escalation or Intensification According to Risk in Pediatric ALL

The UKALL 2003 trial randomly assigned patients to a standard or augmented regimen post remission therapy according to their MRD stratification.